PIK3CA and neoplasm: Two trials have shown significant improvements in progression-free survival with everolimus versus placebo in combination with fulvestrant, although the relative benefits by PI3K pathway status are yet to be reported.20, 21 The activity of the α-specific PI3K inhibitor, alpelisib, in combination with fulvestrant was confined to patients whose tumours harboured PIK3CA mutations.11